New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
10:56 EDTIDRA, ADES, CUR, S, ACNHigh option volume stocks: IDRA ADES CUR S ACN
News For IDRA;ADES;CUR;S;ACN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 29, 2014
12:18 EDTSOn The Fly: Midday Wrap
Subscribe for More Information
10:32 EDTSDreamWorks jumps after report of Softbank takeover talks
Subscribe for More Information
07:15 EDTACNNational Association of Business Economics to hold annual meeting
Subscribe for More Information
September 26, 2014
05:50 EDTSStocks with implied volatility movement; TMUS S
Subscribe for More Information
September 24, 2014
14:10 EDTACNAccenture FY15 guidance below Street not surprising, says Wells Fargo
Subscribe for More Information
09:05 EDTACNOn The Fly: Pre-market Movers
Subscribe for More Information
07:12 EDTACNAccenture sees FY15 new bookings $34B-$36B
Subscribe for More Information
07:11 EDTACNAccenture increases dividend 10% to $1.02 per share
Subscribe for More Information
07:11 EDTACNAccenture sees Q1 revenue $7.55B-$7.8B, consensus $7.8B
Accenture expects net revenues for Q1 of $7.55B-$7.8B, which assumes a foreign-exchange impact of negative 2% compared with the 1Q14.
07:10 EDTACNAccenture sees FY15 EPS $4.74-$4.88, consensus $4.91
Subscribe for More Information
07:07 EDTACNAccenture reports Q4 EPS $1.08, consensus $1.10
Reports Q4 revenue $7.8B, consensus $7.62B. Reports Q4 free cash flow $1.5B. Reports Q4 bookings $8.3B.
September 23, 2014
15:31 EDTACNAccenture October 80 weekly straddle priced for 3.9% move into Q4
Subscribe for More Information
15:27 EDTACNNotable companies reporting before tomorrow's open
Subscribe for More Information
08:07 EDTACNAccenture weekly volatility increases into Q4 and outlook
Accenture September weekly call option implied volatility is at 51, October weekly is at 30, November and January is at 21; compared to its 26-week average of 20 according to Track Data, suggesting large near term price movement into the expected release of Q4 results on September 24.
September 22, 2014
09:19 EDTCURNeuralstem ALS investigator presents long-term follow up Phase I data
Neuralstem announced that Jonathan D. Glass, MD, site investigator at Emory University, presented long-term follow up data on the Phase I trial testing NSI-566 human neural stem cells in the treatment of amyotrophic lateral sclerosis, or ALS. The presentation, which occurred at the Annual Symposium on ALS of the Foundation Andre-Delambre, in Montreal, Canada, on Friday, and was not open to the public, covered data up to approximately 1200 days post the stem cell treatment. Dr. Glass reported that patients in the last safety cohort, who received treatments in both the lumbar and the cervical region with the highest number of cells per injection, all showed significant slowing of the progression of the disease. One patient showed functional improvement from pre-treatment baseline, which is maintained to present day. The other two patients are maintaining the same level of functionality as they had at the baseline for over three years since the stem cell treatment. "The long-term follow up data is very encouraging," said Karl Johe, PhD, Neuralstem's Chairman and Chief Scientific Officer. "In Phase I, patients 10, 11, and 12 each received 10 lumbar and five cervical injections, of 100,000 cells each, which was far below the safe maximal dose. Even so, the data shows a significant slowing of the disease progression for over three years. If replicated on a larger scale, this could represent meaningful improvement in quality of life, and lifespan, compared to untreated patients. In our Phase II dose escalation trial, we successfully reached the maximal dose planned, which consisted of 20 lumbar and 20 cervical injections of 400,000 cells each, more than ten times the number of stem cells delivered in the highest dose cohort of the Phase I trial."
07:14 EDTADESAdvanced Emissions announces the retirement of COO Jean Bustard
Subscribe for More Information
September 19, 2014
07:36 EDTSSprint price target cut to $8-$10 from $11-$11.75 at Wells Fargo
Subscribe for More Information
September 18, 2014
07:19 EDTACNAccenture weekly volatility elevated into Q4 and outlook
Subscribe for More Information
07:14 EDTACNAccenture should be bought on any weakness, says Wells Fargo
Wells Fargo expects Accenture to report in-line Q4 results but believes that its initial FY15 guidance could come in below expectations, partly due to reduced IT spending this year by some enterprises. However, the firm still thinks that the company has "the most admirable" IT services business" and recommends buying the stock on any near-term weakness caused by a guidance miss. It keeps an Outperform rating on the shares.
September 17, 2014
12:53 EDTSSprint management to meet with Jefferies
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use